APA (7th ed.) Citation

Yueming He, Yitao Wu, Rongqi He, Meng Xu, Heshan Chen, Yiran Meng, . . . Li Wang. (2024). Case report: Favorable efficacy of combined afatinib and anlotinib treatment in a lung adenocarcinoma patient harboring uncommon EGFR L858M/L861R mutations. Frontiers Media S.A..

Chicago Style (17th ed.) Citation

Yueming He, Yitao Wu, Rongqi He, Meng Xu, Heshan Chen, Yiran Meng, Liuqing Zheng, and Li Wang. Case Report: Favorable Efficacy of Combined Afatinib and Anlotinib Treatment in a Lung Adenocarcinoma Patient Harboring Uncommon EGFR L858M/L861R Mutations. Frontiers Media S.A., 2024.

MLA (9th ed.) Citation

Yueming He, et al. Case Report: Favorable Efficacy of Combined Afatinib and Anlotinib Treatment in a Lung Adenocarcinoma Patient Harboring Uncommon EGFR L858M/L861R Mutations. Frontiers Media S.A., 2024.